v3.26.1
Accounts payable and accrued liabilities
 3 Months Ended
Mar. 31, 2026
Notes and other explanatory information [abstract]  
Accounts payable and accrued liabilities

 

7.Accounts payable and accrued liabilities

 

The Company had the following accounts payable and accrued expenses at the end of each reporting period:

 

   March 31, 2026   December 31, 2025 
   $   $ 
Trade accounts payable   594    745 
Accrued research and development costs   -    59 
Accrued employee benefits   43    471 
Payroll tax and other statutory liabilities   -    (13)
Other accrued liabilities   289    621 
Payables and accrued liabilities   926    1,883 

 

 

COSCIENS Biopharma Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of March 31, 2026, and for the three months ended March 31, 2026, and 2025

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)